section name header

Evidence summaries

Pharmacotherapy for Hyperuricemia in Hypertensive Patients

There is insufficient evidence whether uric acid lowering therapy is effective in lowering blood pressure in patients with hyperuricemia and hypertension. Level of evidence: "D"

The quality of evidence is downgraded by inconsistency (variability in results), by indirectness (differences between outcomes of interest and those studied: only short-term outcomes reported), and by imprecise results (few patients).

Summary

A Cochrane review [Abstract] 1 included 3 studies with a total of 211 subjects with hypertension or prehypertension, plus hyperuricaemia. The aim of this review was to determine whether or not treatment for hyperuricemia also results in a reduction of blood pressure (BP) in prehypertensive or hypertensive patients.

No significant differences were observed in 24-hour ambulatory systolic (MD -6.2 mmHg, 95% CI -12.8 to 0.5; 3 studies, n=229) or diastolic BP (-3.9 mmHg, 95% CI -9.2 to 1.4; 3 studies, n=229) between those who received uric acid (UA)-lowering drugs and placebo.UA-lowering drugs reduced clinic-measured systolic BP (-8.43 mmHg, 95% CI -15.24 to -1.62; 2 studies, n=120) but results for clinic-measured diastolic BP were inconclusive (-6.45 mmHg, 95% CI -13.60 to 0.70; 2 studies, n=120).Serum UA levels were reduced by 3.1 mg/dL (95% CI 2.4 to 3.8; 3 studies, n=223) in the participants that received UA-lowering drugs.Results were inconclusive regarding the occurrence of adverse events between those who received UA-lowering drugs and placebo (RR 1.86, 95% CI 0.43 to 8.10; 3 studies, n=241).

Clinical comments

Note

Date of latest search:

    References

    • Gois PHF, Souza ERM. Pharmacotherapy for hyperuricaemia in hypertensive patients. Cochrane Database Syst Rev 2020;(9):CD008652. [PubMed]

Primary/Secondary Keywords